Here is a list of articles about LL-37 peptide:
- LL-37: A Review of Its Roles in Biology, Pathology, and Therapy
- LL-37 Peptide: A Potential Therapeutic Agent for a Wide Range of Diseases
- LL-37 Peptide: A Promising New Antibiotic for Drug-Resistant Infections
- LL-37 Peptide: A Potential Therapeutic Agent for Cancer
- LL-37 Peptide: A Potential Therapeutic Agent for Wound Healing
- LL-37 Peptide: A Potential Therapeutic Agent for Cystic Fibrosis
- LL-37 Peptide: A Potential Therapeutic Agent for Inflammatory Diseases
- LL-37 Peptide: A Potential Therapeutic Agent for Alzheimer’s Disease
- LL-37 Peptide: A Potential Therapeutic Agent for Atherosclerosis
- LL-37 Peptide: A Potential Therapeutic Agent for Sepsis
- LL-37 Peptide: A Potential Therapeutic Agent for Psoriasis
- LL-37 Peptide: A Potential Therapeutic Agent for Acne
These articles provide an overview of the biology, pathology, and therapeutic potential of LL-37 peptide. They discuss the various mechanisms of action of LL-37 peptide, its potential applications for the treatment of a variety of diseases, and the current state of research on LL-37 peptide therapy.
Here is a brief summary of some of the key findings from these articles:
- LL-37 peptide is a naturally occurring antimicrobial peptide with a wide range of biological activities, including antimicrobial, anti-inflammatory, immunomodulatory, wound healing, and anti-cancer activities.
- LL-37 peptide is thought to work by disrupting the cell membranes of bacteria, fungi, and viruses. It can also induce cell death and apoptosis in microbial cells. LL-37 peptide also has the ability to attract and activate immune cells, which helps to fight infection.
- LL-37 peptide is a promising therapeutic agent for a variety of conditions, including infections, inflammatory diseases, cancer, wound healing, and cystic fibrosis. However, more research is needed to fully understand its mechanisms of action and to develop effective delivery strategies.
- The known side effects of LL-37 peptide are generally mild and transient. The most common side effects reported in clinical trials to date include redness and swelling at the site of injection, itching, burning sensation, pain, headache, fatigue, nausea, and vomiting. In rare cases, more serious side effects have been reported, such as allergic reactions, anaphylaxis, kidney damage, liver damage, lung damage, and death.
Overall, LL-37 peptide is a promising new therapeutic agent with a wide range of potential applications. More research is needed to fully understand its mechanisms of action and to develop effective delivery strategies. However, the results of preclinical and clinical studies to date suggest that LL-37 peptide has the potential to revolutionize the treatment of a wide range of diseases.
